Analysis-Novo's stumbles burnish Lilly's widening lead in weight-loss drugs [Yahoo! Finance Canada]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance Canada
LONDON, Feb 24 (Reuters) - With U.S. arch rival Eli Lilly streaking away on weight-loss prescriptions and valuation, the last thing Novo Nordisk needed was to give it a helping hand. Then came the latest trial data for the Danish company's ?next-generation obesity drug. Novo unveiled late-stage trial data for its CagriSema drug on Monday that not only showed it underperforming Lilly's rival Zepbound, but appeared ?to show weight loss with Zepbound was better than even some of Lilly's own data had shown. Novo's shares tanked 16% while Lilly jumped 5% as the trial data raised doubts about the Danish ?company's obesity drug pipeline and ability to claw back ground that it has lost in recent years as competition in the market has hardened. "They literally ran a trial that said that Lilly's product is better," said BMO Capital analyst Evan Seigerman, adding that even with more trials ahead, it would be tough to win over investors after twin misses with CagriSema in just over a year.
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly and Company (LLY) is now covered by Royal Bank Of Canada. They set an "outperform" rating on the stock.MarketBeat
- Novo downgraded at J.P. Morgan as next-gen obesity drug trails Lilly's Zepbound [Seeking Alpha]Seeking Alpha
- Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen [MSNBC.com]MSNBC.com
- Eli Lilly launches new form of obesity drug Zepbound with a month's worth of doses in one pen [CNBC]CNBC
- Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPenPR Newswire
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 2/19/26 - Form 4
- 2/18/26 - Form 4
- 2/18/26 - Form 4
- LLY's page on the SEC website